Telink Semiconductor (Shanghai) Co., Ltd. (688591.SH) reported a 10.86% year-on-year increase in revenue for the first three quarters; the edge AI segment is currently in the R&D validation stage.
On the evening of October 27, Telink Semiconductor (688591.SH) disclosed its 2026 third-quarter report.
On the evening of October 27, Telink Semiconductor (Shanghai) Co., Ltd. (688591.SH) disclosed its Q3 2026 report. In the first three quarters, it achieved operating revenue of RMB850 million, up 10.86% year on year; and net profit attributable to shareholders of the listed company of RMB127 million. In Q3 alone, it achieved operating revenue of RMB309 million, up 17.54% year on year, and net profit attributable to parent of RMB28.6744 million, with revenue continuing its growth trend.
Edge AI R&D projects continue to advance, new-form terminals expected to move toward mass production
Telink Semiconductor (Shanghai) Co., Ltd. stated that revenue growth in the first three quarters was mainly driven by growing market demand. Q3 revenue growth was further above the overall level for the first three quarters. Alongside the expansion in revenue scale, the company's gross profit increased by RMB30.6234 million year on year, an increase of 7.88%.
From an industry perspective, the edge AI industry is currently in a stage of continuous new product R&D and industrialization. A recent research report by China Merchants Electronics judged that despite the impact of memory price increases, AI edge R&D projects by brands and model makers have not stopped; in 2026, major manufacturers' new products will mainly be phone system-level Agents and AI glasses, with cloud-resident Agents also starting up; from Q4 2026 to 2027, edge AI catalysts will be dense, and new-form terminals are expected to move from concept to mass production.
The research report compiled statistics showing that OpenAI's first hardware has entered the EVT stage, Apple's smart glasses, AirPods with cameras and other products are advancing, and domestic manufacturers are also exploring product forms such as AI glasses, recording cards, brooches, pendants and companion Siasun Robot&Automation. China Merchants Electronics judged that around Q1 2027 will be a key node for hit products to emerge.
In the process of edge AI new-form terminals moving from concept to mass production, sustained R&D validation and investment are important support for industry chain companies to advance product commercialization
R&D investment up 31.42% year on year, technology reserves continuously strengthened
Broadly in line with the industry's rhythm of being in the R&D validation stage, Telink Semiconductor (Shanghai) Co., Ltd. invested a cumulative RMB244 million in R&D in the first three quarters, up 31.42% year on year, significantly higher than revenue growth in the same period; R&D investment as a proportion of operating revenue was 28.74%, up 4.50 percentage points from the same period last year. In Q3, the company's R&D investment was RMB82.3378 million, up 18.91% year on year, accounting for 26.65% of operating revenue in the period. Maintaining R&D intensity is a prerequisite for subsequent product commercialization and performance release.
Regarding the increase in R&D investment, the company's announcement shows that as various R&D projects advance, the company continues to expand its R&D technical team, with R&D compensation, software and IP licensing fees and other expenses all increasing. Against the backdrop of rapid technological iteration in the wireless IoT chip industry, sustained R&D investment helps the company advance product and technology reserves and provides support for subsequent business expansion.
According to public information, Telink Semiconductor (Shanghai) Co., Ltd. is mainly engaged in the R&D, design and sales of wireless IoT system-on-chips, with an extremely broad range of main product areas and diverse customer industries, including but not limited to smart home, edge AI, low-latency wireless audio, smart remote controls, automotive electronics, human-machine interaction, gaming and esports, smart wearables, healthcare, smart retail, smart industry and smart lighting. Around its main business of wireless IoT system-on-chips, the revenue growth and increased R&D investment disclosed this time by Telink Semiconductor (Shanghai) Co., Ltd. show a pattern of business scale expansion and technology investment advancing in parallel.
In terms of asset scale, as of September 30, 2026, Telink Semiconductor (Shanghai) Co., Ltd. had total assets of RMB2.725 billion, up 4.26% from the end of the previous year; owners' equity attributable to shareholders of the listed company was RMB2.560 billion, up 5.16% from the end of the previous year. At the end of the reporting period, the company had monetary funds of RMB1.195 billion and trading financial assets of RMB640 million; total liabilities were RMB165 million. Calculated based on the reported data, the debt-to-asset ratio was approximately 6.05%, and the financial structure remained sound.
Overall, Telink Semiconductor (Shanghai) Co., Ltd. maintained revenue growth in the first three quarters, with Q3 revenue growth further improving year on year; at the same time, the company maintained high R&D intensity and had relatively ample asset and capital reserves. As the downstream industry matures and R&D projects continue to be commercialized, Telink Semiconductor (Shanghai) Co., Ltd.'s subsequent product and market developments warrant continued attention.
Related Articles

Victory Giant Technology (02476) plans to make additional investments of no more than US$800 million and US$700 million in its wholly-owned indirect subsidiaries Victory Giant Technology (Thailand) and Victory Giant Technology (Vietnam), respectively.
MICROPORT (00853): Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. reported a net profit attributable to shareholders of RMB449 million for the first three quarters, up 4.55% year on year.

KEYMED BIO-B (02162) intends to purchase shares under the 2022 Restricted Share Unit Plan.
Victory Giant Technology (02476) plans to make additional investments of no more than US$800 million and US$700 million in its wholly-owned indirect subsidiaries Victory Giant Technology (Thailand) and Victory Giant Technology (Vietnam), respectively.

MICROPORT (00853): Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. reported a net profit attributable to shareholders of RMB449 million for the first three quarters, up 4.55% year on year.
KEYMED BIO-B (02162) intends to purchase shares under the 2022 Restricted Share Unit Plan.






